E76.211 Morquio B mucopolysaccharidoses

Name of the Condition

• Morquio B mucopolysaccharidoses (ICD-10 Code: E76.211)

Summary

Morquio B mucopolysaccharidoses are a rare inherited disorder characterized by the accumulation of glycosaminoglycans (GAGs) due to enzyme deficiencies. This buildup disrupts normal cellular function, leading to progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early recognition and management are important to address complications and slow disease progression.

Causes

The disorder is caused by genetic mutations that impair enzymes responsible for breaking down glycosaminoglycans. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of mucopolysaccharidoses or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features.

Diagnosis

Diagnosis involves clinical evaluation, biochemical testing to measure enzyme activity, and genetic testing to identify mutations. Urine analysis may detect elevated GAG levels, and imaging studies can assess skeletal and organ involvement. A multidisciplinary approach is often used to confirm the diagnosis and rule out other conditions.

Treatment Options

Treatment focuses on managing symptoms and complications. Enzyme replacement therapy may be used to reduce GAG accumulation. Supportive care includes physical therapy, orthopedic interventions, and monitoring for organ dysfunction. Clinical trials may offer additional therapeutic options.

Prognosis and Follow-Up

Prognosis varies based on disease severity and organ involvement. Regular follow-up with specialists is essential to monitor progression, adjust treatments, and address complications. Early intervention can improve quality of life and slow disease advancement.

Complications

Complications may include respiratory issues, cardiac problems, vision or hearing loss, and spinal cord compression. Progressive skeletal abnormalities can lead to mobility challenges. Organ dysfunction may require targeted management.

Lifestyle & Prevention

Lifestyle modifications, such as adaptive equipment and physical therapy, can support mobility. Genetic counseling is recommended for families to understand inheritance risks. Prenatal testing may be considered for at-risk pregnancies.

When to Seek Professional Help

Seek medical attention for new or worsening symptoms, such as severe pain, breathing difficulties, or neurological changes. Regular check-ups are important for monitoring disease progression and adjusting care plans.

Tips for Medical Coders

Document clinical findings, diagnostic tests, and treatment plans to support code assignment. Ensure specificity in documentation to differentiate Morquio B from other mucopolysaccharidoses. Include details on enzyme deficiencies or genetic test results when available.